---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-007198"
form_type: "8-K"
ticker: "IMNM"
cik: "0001472012"
company_name: "Immunome Inc."
filed_at: "2025-01-29T23:59:59+00:00"
generated_at: "2026-05-27T06:44:02.053421+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Immunome launches public offering of common stock; pipeline update with Phase 3 data H2 2025

## Summary
- Underwritten public offering of common stock commenced; size not disclosed.
- Preliminary cash, equivalents and marketable securities $217.3M as of Dec 31, 2024.
- Varegacestat Phase 3 desmoid tumor trial fully enrolled; topline data expected H2 2025.
- IM-1021 (ROR1 ADC) IND cleared Dec 2024; Phase 1 starts Q1 2025 at 2 mg/kg starting dose.
- IM-3050 (FAP RLT) IND submission expected Q1 2025; three ADCs in IND-enabling manufacturing.

## SEC filing metadata
- accession: 0001104659-25-007198
- form_type: 8-K
- ticker: IMNM
- cik: 0001472012
- company_name: Immunome Inc.
- filed_at: 2025-01-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472012/000110465925007198/0001104659-25-007198-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472012/000110465925007198/tm254675d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-007198
- JSON: https://secwatch.observer/filing/0001104659-25-007198.json
- Plain text: https://secwatch.observer/filing/0001104659-25-007198.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.